ArticleCardiovascular diabetology2010
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.
Article in Cardiovascular diabetology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials.African health sciences · 2021Pooled it
- Trial
- Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial.Scientific reports · 2016Trial
- Trial
- Trial
- Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.Endocrine oncology (Bristol, England) · 2026Article
- Identification of Preclinical Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease versus Metabolic Dysfunction and Alcohol-Associated Liver Disease and the Impact of Diet.The American journal of pathology · 2026Article
- Preliminary evaluation of oxyntomodulin as a biomarker for metabolic risk stratification in adults with obesity.Journal of translational medicine · 2025Article
- The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study.The Journal of clinical endocrinology and metabolism · 2024Article
- Correlation between time in range and serum uric acid in Chinese patients with type-2 diabetes: an observational cross-sectional study.Diabetology & metabolic syndrome · 2024Article
- Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.Acta diabetologica · 2022Article
- Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.Future science OA · 2022Article
- Effects of Rapamycin on Insulin Brain Endothelial Cell Binding and Blood-Brain Barrier Transport.Medical sciences (Basel, Switzerland) · 2021Article
- Decreased Glucagon-Like Peptide-1 Is Associated With Calcific Aortic Valve Disease: GLP-1 Suppresses the Calcification of Aortic Valve Interstitial Cells.Frontiers in cardiovascular medicine · 2021Article
- Potential of Glucagon-Like Peptide 1 as a Regulator of Impaired Cholesterol Metabolism in the Brain.Advances in nutrition (Bethesda, Md.) · 2020Review
- Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years.Diabetes/metabolism research and reviews · 2020Article
- An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity.The Journal of international medical research · 2019Article
- GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals.Cardiovascular diabetology · 2019Article
- Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study.Molecules (Basel, Switzerland) · 2018Article
- Effect of fermented camel milk on glucose metabolism, insulin resistance, and inflammatory biomarkers of adolescents with metabolic syndrome: A double-blind, randomized, crossover trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide-1 (GLP-1) is an incretin hormone that has a wide range of effects on glucose metabolism and cardiovascular function (e.g., improving insulin sensitivity, reduction in appetite, modulation of heart rate, blood pressure and myocardial contractility). Metabolic syndrome (MetS) is associated with an increased risk of developing atherosclerotic cardiovascular diseases. Novel glycemic control drugs, the dipeptidyl-peptidase-4 (DPP-4) inhibitors, work by inhibiting the inactivation of incretin hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role in MetS are largely unknown.
methodsTo examine relationships between incretin hormones and MetS risk factors, we measured circulating levels of incretins in obese high-risk patients for cardiovascular disease. Fasting serum GLP-1 and GIP levels were measured by ELISA. We performed a cross-sectional analysis of metabolic variables in the fasting state in two subject groups: with MetS (n = 60) and pre-MetS (n = 37).
resultsFasting levels of Serum GLP -1 in the peripheral circulation were significantly increased correlated with the accumulation of MetS risk factors components (r = 0. 470, P < 0.001). There was a significant interaction between circulating GLP-1 and GIP, serum high-density lipoprotein cholesterol, triglyceride, and serum uric acid concentrations but not waist circumference, fasting glucose, HbA1c, or presence of diabetes.
conclusionCirculating levels of GLP-1 in relation to the accumulation in MetS factors suggested that MetS patients with elevated levels of GLP-1 are high-risk patients for cardiovascular disease, independent with the presence of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.